Does Biosilicon deliver? Uni of Pittsburgh to investigate
Friday, 21 May, 2004
Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
The company will work with the laboratory of Prof Ted Ross, which has experience in developing DNA vaccines for viral diseases to build on prior work performed by pSiMedica on the loading into and release of DNA from BioSilicon matrices to effectively produce the immunogen carried by the DNA sequence.
pSivida managing director Gavin Rezos said the agreement demonstrated the increasing profile of pSivida and pSiMedica in the US.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
